The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

08 July 2025 via Zoom Final Agenda The meeting will take place via Zoom, a secure web conferencing tool. The meeting will run from 9:00am although this may be subject to change. Joining links and ...

Our updated guideline reflects this change in practice and in doing so they recommend an earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozinthan we’ve recommended before. It means they ...

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin with bortezomib and dexamethasone within its marketing authorisation for treating relapsed or refractory ...

Home NICE guidance In development PillCam COLON 2 for investigation of the colon through direct visualisation ...

What this means in practice Obe‑cel is not required to be funded in the NHS in England to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia in adults. It should not be used ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. The guidance recommends the ...

Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...

Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. Last reviewed: 24 June 2025 Next review: ...

Marstacimab is recommended, within its marketing authorisation, as an option for preventing bleeding episodes caused by severe (factor IX [9] activity less than 1%) haemophilia B (congenital factor 9 ...